Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 993-993
Author(s):  
Irene M. Ghobrial ◽  
Mona Melhem ◽  
Ujjal Singha ◽  
Diane George ◽  
Michael Timm ◽  
...  

Abstract Waldenstrom Macroglobulinemia (WM) is characterized by the presence of lymphoplasmacytic cells in the bone marrow, and often in the lymph nodes. The mechanisms by which cells migrate/home to the bone marrow are poorly understood. The chemokine receptor CXCR4 and its ligand SDF-1 have been implicated in the migration and homing of lymphocytes. The objective of this study was to begin to identify the role of CXCR4 in WM. Paraffin embedded tissues were obtained after informed consent from 10 bone marrow samples of asymptomatic WM/monoclonal gammopathy of undetermined significance (MGUS) (n=5) and symptomatic WM (n=5). Four normal bone marrow samples were obtained for control. CXCR4 expression was determined using anti-CXCR4 antibody (Affinity Bioreagents, Golden, CO) 1:200 dilution for 16hrs, and a scale of 0–3+ was used to determine relative expression in the lymphocytes. Anti-CD20 antibody was used to determine the presence of lymphocytes in the samples. To determine whether the receptor is functional, migration was performed with the WM cell line (WSU-WM, kind gift from Dr. Al-Khatib, Wayne State University) and using a transwell migration assay (Costar, Corning, NY) with serial dilutions of SDF-1 (10-100nM). Comparison between the asymptomatic and symptomatic WM groups was performed by c2 test, and Mann-Whitney test, as appropriate. The baseline patient characteristics are displayed in table 1. CXCR4 expression was present on the surface of scattered lymphocytes in the normal bone marrow (median expression 1+). The expression of CXCR4 was increased in the asymptomatic/MGUS cases of WM (median expression 2+). In contrast, CXCR4 expression was downregulated in 4/5 cases of symptomatic WM specifically all the ones with extensive involvement of the bone marrow with lymphoplasmacytic cells (median expression 0). SDF-1 induced a bell- shaped response of migration in the WM cells with the maximal migration occurring at 1-10nM SDF-1. SDF-1 1-10nM induced 340% increase in migration as compared to untreated cells. However, high doses of SDF-1 100nM did not induce any migration as compared to untreated cells indicating inhibition of migration in response to high doses of SDF-1. In summary, we demonstrate that the CXCR4 receptor is functional and induces migration indicating that it plays a role in the migration of WM cells to the bone marrow. In addition, we demonstrate that CXCR4 expression is downregulated in WM with high infiltration of cells in the bone marrow as compared to those with minimal infiltration. These results may be due to the high level of SDF-1 in the bone marrow that induce downregulation of CXCR4. High levels of SDF-1 may downregulate the receptor and inhibit migration in order to confine the cells within the bone marrow. Supported in part by an ASH scholar award and the RFW. Patient characteristics Asymptomatic WM/MGUS, (range), (N=5) Symptomatic WM, (range) (N=5) Median age at diagnosis 67.6 (55.8–78) 71.5 (61–77) Median IgM level (mg/dL) 997 (904–1490) 5410 (2000–7820) Median Hb (gm/dL) 12.6 (11.1–15.1) 10.8 (9.3–11.6) Organomegaly (liver or spleen) N 20% Lymphadenopathy N 40% Median involvement of tumor cells in the BM in % 5% 30(10–60)

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1540-1540 ◽  
Author(s):  
Vijaya Pooja Vaikari ◽  
Miran Jang ◽  
Mojtaba Akhtari ◽  
Houda Alachkar

Abstract Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by clonal proliferation and block of differentiation of myeloid precursors. Overall survival for patients with AML remains dismal (<50% for younger patients and <10% for older patients) due to high relapse rate. In search for novel therapeutic targets in AML, we compared gene expression data of normal hematopoietic vs AML cells from 7 datasets (GSE13159, GSE13164, GSE7186, GSE1159, GSE995, GSE31174 and TCGA Leukemia) available on Oncomine. We identified CD99 to be significantly upregulated in AML cells compared with normal cells in all data sets with available measurements of CD99 expression (median ranking 155, p = 0.013); other genes among the top 10 genes identified in this analysis were FLT3 (median ranking 102, p<0.001) and WT1 (median ranking 120, p<0.001); both are known to play a role in AML. CD99 was significantly over-expressed (p<0.001) in 542 AML patients as compared with PBMCs from 74 healthy donors from the GSE13159 dataset. In the GSE13164 dataset, CD99 was significantly over-expressed in 257 AML patients as compared with PBMCs from 58 healthy donors. Consistently, in the GSE7186 dataset, CD99 was significantly over-expressed (p<0.001) in 23 AML patients as compared with 6 normal bone marrow samples and in the GSE1159 dataset, CD99 was significantly over-expressed (p=0.001) in 285 AML patients as compared with 5 normal bone marrow, and 3 normal blood samples. We also analyzed CD99 expression in cells obtained from 23 patients with AML and sorted according to their CD34 and CD38 expression levels (GSE3077 dataset). We found that CD99 expression was significantly higher (p<0.001) in the CD34+CD38+ and CD34+CD38- subpopulation compared with CD34-CD38- and CD34-CD38+; suggesting a possible role of CD99 in AML stem cells. Interestingly, analysis of three datasets (GSE22848, GSE6891, GSE15434) via R2: Genomics Analysis and Visualization Platform showed a correlation between CD99 expression and the presence of FLT3-ITD mutation. In the GSE22848 dataset, CD99 was significantly over-expressed (p=0.007) in 48 patients with FLT3-ITD as compared with 189 patients with FLT3 wildtype. In the GSE6891 dataset, 126 patients with FLT3-ITD had a significant over-expression of CD99 (p=0.006) as compared with 334 patients with FLT3 wildtype and in the GSE15434 dataset 90 FLT3-ITD positive patients had significantly higher levels of CD99 (p<0.001) as compared with 161 patients with the wildtype gene. CD99 (E2, MIC2), a 32-kD cell surface glycoprotein, is known to be involved in the transendothelium migration of neutrophils, T-cell adhesion, and T-cell death by a caspase-independent pathway. In cancer cells, CD99 was found to be highly expressed on the cell surface of Ewing's sarcoma tumors and in gliomas. Importantly, CD99 expression levels were found to be correlated with tumor invasiveness and with lower survival rates. In order to examine the role of CD99 in AML, we assessed CD99 expression by flow cytometry in nine AML cell lines (KG-1, KG-1A, MOLM13, MV4-11, Kasumi-1, THP-1, NB4, U937, UOC-M1); we found CD99 to be expressed in all cell lines. To determine whether CD99 is a potential therapeutic target in AML, we treated leukemia cells with anti-CD99 mAb (mAb 0662) at 5 µg/mL and analyzed cell viability 48 hours post-treatment. We found significant decrease in cell viability; 15% in MV4-11 cells (p=0.02), 32% in MOLM13 cells (p=0.002) and 18% in THP-1 cells (p<0.001) as compared with untreated controls measured by Alamar blue assay. Furthermore, inhibiting CD99 led to a decrease in migration of MV4-11, MOLM13 and THP-1 cells when analyzed using a trans-well migration assay. In conclusion, CD99 is highly expressed in AML, and this expression is significantly higher in less differentiated leukemia cells and in patients with FLT3-ITD mutation. Functional studies using CD99 antibodies revealed a possible role of this gene in cell survival and cell migration. Further studies are needed to establish CD99 as a potential therapeutic target and further investigations are ongoing to determine the mechanism by which CD99 regulates cell survival in AML. Disclosures No relevant conflicts of interest to declare.


2005 ◽  
Vol 22 (1) ◽  
pp. 39-46 ◽  
Author(s):  
Neslihan Cabioglu ◽  
Aysegul Sahin ◽  
Michele Doucet ◽  
Ekrem Yavuz ◽  
Abdullah Igci ◽  
...  

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1322-1322
Author(s):  
David C. de Leeuw ◽  
Fedor Denkers ◽  
Peter J. Valk ◽  
Gerrit Jan Schuurhuis ◽  
Gert J. Ossenkoppele ◽  
...  

Abstract Over the last past years microRNAs (miRNAs) have emerged as important regulators of normal hematopoiesis. Growing evidence suggests that miRNAs that are expressed and function in hematopoietic stem cells (HSC) are especially important in the pathogenesis of acute myeloid leukemia (AML). HSC characteristics like self renewal, quiescence and the ability to overcome senescence have shown to be under control of miRNAs and contribute to the aggressiveness of AML. Recently we identified microRNA-551b (miR-551b) as a miRNA that is highly expressed in residual normal HSC in AML bone marrow. Thus far, no functional or clinical relevance has been described for miR-551b. To explore its clinical impact we here investigate the expression of miR-551b in highly enriched stem and progenitor cell populations in normal bone marrow and in a cohort of AML patients. Normal bone marrow showed highest expression of miR-551b in the two most primitive CD34+CD38- populations i.e. CD90+CD45RA- HSC and CD90-CD45RA- multipotent progenitor cells. In the more differentiated progenitor and mature cell populations, miR-551b expression was strongly reduced suggesting its involvement in early hematopoiesis (Figure A). To investigate whether miR-551b is expressed and of prognostic importance in AML we performed qRT-PCR expression analysis in well defined de novo AML bone marrow samples (n=154). High miR-551b expression was associated with lower complete remission (CR) rates after first-line standard-dose remission-induction therapy (p=.015) and shorter relapse free survival (RFS; p=.003) and overall survival (OS; p<.005) (Figure B/C). Also in cytogenetically normal AML high expression was associated with poor outcome (OS p=.02 and RFS p=.009). Combining miR-551b expression at diagnosis with minimal residual disease (MRD) detection after the second cycle of chemotherapy improved the prognostic value of MRD detection. Patients who were positive for MRD and/or highly expressed miR-551b showed shorter OS (p=.01) and RFS (p=.001) compared to patients who were both MRD negative and had low miR-551b expression. Moreover, in the group of MRD negative patients a higher chance of relapse was found if patients expressed miR-551b highly compared to those with low expression (66.7 vs. 27.6%). In multivariate analysis, high miR-551b expression remained an independent predictor for overall survival (p=.049) and relapse free survival (p=.001). In line with miR-551b being an early hematopoietic miRNA, high expression was correlated with more undifferentiated morphology. To shed more light on the biological role of miR-551b we correlated its expression to mRNA sequencing data in a large publically available dataset [Ley et al., NEJM 2013]. Many of the genes that highly correlated with miR-551b like: MLLT3, INPP4B, HTR1F, HOPX, PROM1 and others, are also present in published HSC gene signatures. Gene ontology analysis of the correlated genes showed significant enrichment for genes involved in hematopoiesis and cell adhesion. Our results show that miR-551b is a HSC specific miRNA and that high expression in AML is associated with a poor prognosis possibly because it reflects a stem cell-like state. Currently our research focuses on the functional role of miR-551b in normal and malignant hematopoiesis. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document